沙库巴曲缬沙坦钠与贝那普利治疗高龄射血分数降低型慢性心力衰竭患者效果观察

Observation of the effects of sacubatril and valsartan and benazepril on elderly patientswith chronic heart failure and reduced ejection fraction

目的:分析沙库巴曲缬沙坦钠与贝那普利治疗高龄射血分数降低型慢性心力衰竭患者的效果。方法:选取2018年1月至2019年6月收治的82例射血分数降低型慢性心力衰竭高龄患者为研究对象,随机分为观察组和对照组两组;观察组患者使用沙库巴曲缬沙坦钠治疗,对照组患者使用贝那普利治疗,比较两组患者的临床疗效,治疗前后心功能指标、IL-1、IL-6、hs-CRP、血肌酐及NT-proBNP,并分析不良反应发生情况。结果:观察组患者的临床疗效总有效率为95.12%,高于对照组患者的80.49%(P<0.05);治疗前两组患者的心功能指标差异无统计学意义(P>0.05),治疗后两组患者的LVEDV、LVESE指标均下降(P<0.05),LVEF指标均上升(P<0.05),且治疗后观察组患者的LVEDV、LVESE、LVEF指标改善更多(P<0.05);治疗前两组患者的IL-1、IL-6、hs-CRP水平相比,差异无统计学意义(P>0.05),治疗后两组患者的IL-1、IL-6、hs-CRP水平均下降(P<0.05),且治疗后观察组患者的IL-1、IL-6、hs-CRP水平下降更多(P<0.05);两组患者治疗前后血肌酐水平比较,差异无统计学意义(P>0.05),治疗后两组患者的NT-proBNP水平均下降(P<0.05),且治疗后观察组患者的NT-proBNP水平下降更多(P<0.05);两组患者的不良反应发生率分别为9.76%和12.20%,组间相比,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠治疗高龄射血分数降低型慢性心力衰竭患者可提高临床疗效,改善患者心功能,降低NT-proBNP水平和炎症水平,且安全性高。

Objective:To analyze the effects of sacubitril and valsartan and benazepril on elderly patients with chronic heart failure and reduced ejection fraction.Methods:82 patients with chronic heart failure and reduced ejection fraction hospitalized from January 2018 to June 2019 were chosen and randomly divided into the observation group and the control group.The observation group were treated with sacubitril and valsartan,while the control group were treated with benazepril,with the clinical effects,the cardiac function indexes before and after treatment,IL-1.IL-6,hs-CRP,blood creatinine and NT-proBNP compared,and the occurrence of adverse reactions analyzed.Results:The total effective rate of the observation group was 95.12%,higher than that of the control group(80.49%)(P<0.05);there was no significant difference in cardiac function indexes between the two groups before treatment(P>0.05).After treatment,the LVEDV and LVESE indexes decreased significantly and the LVEF index increased significantly in both groups(P<0.05),with the LVEDV,LVESE and LVEF indexes of the observation group improved more significantly(P<0.05);there was no significant difference in the levels of IL-1,IL-6 and hs-CRP between the two groups before treatment(P>0.05).After treatment,the levels of IL-1,IL-6,and hs-CRP in both groups decreased significantly,with those of the observation group decreased more significantly(P<0.05);there was no significant change in serum creatinine levels in the two groups before and after treatment(P>0.05).After treatment,the levels of NT-proBNP in both groups decreased significantly after treatment,with that of the observation group decreased more significantly(P<0.05).The incidence of adverse reactions in the two groups were 9.76%and 12.20%respectively,there being no significant difference(P>0.05).Conclusion:Sacubatraz and valsartan is safe in improving the clinical efficacy of elderly patients with chronic heart failure and reduced ejection fraction and the patients’heart function,and in reducing the levels of NT-proBNP and inflammation.